

Inken Hilgendorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8157301/publications.pdf>

Version: 2024-02-01

99
papers

2,012
citations

279487

23
h-index

288905

40
g-index

111
all docs

111
docs citations

111
times ranked

3083
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1481-1492.	1.2	1
2	The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. <i>Annals of Hematology</i> , 2022, 101, 919-920.	0.8	3
3	Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2539-2548.	1.2	2
4	Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3191-3202.	1.2	14
5	High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 337.e1-337.e10.	0.6	13
6	Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1164-1170.	1.3	4
7	Comparison of fludarabine+melfhalan and fludarabine+treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	1.3	6
8	Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. <i>American Journal of Hematology</i> , 2022, 97, 1023-1034.	2.0	17
9	Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort. <i>Oncology Research and Treatment</i> , 2022, 45, 494-503.	0.8	2
10	Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 363-374.	1.7	26
11	Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. <i>Bone Marrow Transplantation</i> , 2021, 56, 101-109.	1.3	12
12	Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1239-1246.	1.2	22
13	Melphalan 200 mg/m ² does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients. <i>Bone Marrow Transplantation</i> , 2021, 56, 1209-1212.	1.3	3
14	Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease—results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. <i>Bone Marrow Transplantation</i> , 2021, 56, 243-256.	1.3	11
15	Long-Term Follow-Up of Children, Adolescents, and Young Adult Cancer Survivors. <i>Oncology Research and Treatment</i> , 2021, 44, 184-189.	0.8	14
16	HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient. <i>Annals of Hematology</i> , 2021, 100, 1895-1897.	0.8	2
17	Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN- γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. <i>Diagnostics</i> , 2021, 11, 312.	1.3	2
18	Current practice in nutrition after allogeneic hematopoietic stem cell transplantation—Results from a survey among hematopoietic stem cell transplant centers. <i>Clinical Nutrition</i> , 2021, 40, 1571-1577.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2118-2124.	1.3	6
20	Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	1
21	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , the, 2020, 7, e28-e39.	2.2	94
22	Detection of community-acquired respiratory viruses in allogeneic stem cell transplant recipients and controls A prospective cohort study. <i>Transplant Infectious Disease</i> , 2020, 22, e13415.	0.7	7
23	A 19-year-old patient with atypical chronic myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1145-1148.	0.8	0
24	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2019, 134, 892-899.	0.6	110
25	The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. <i>Annals of Hematology</i> , 2019, 98, 713-722.	0.8	36
26	A Mosquito Bite with Devastating Complications in an Immunocompromised Patient. <i>Case Reports in Oncology</i> , 2019, 12, 22-28.	0.3	2
27	Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1450-1455.	2.0	12
28	Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S3.	2.0	2
29	In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019001.	0.5	38
30	Neue Strukturen in der Betreuung und Nachsorge junger Krebspatienten. <i>Oncology Research and Treatment</i> , 2019, 42, 21-26.	0.8	2
31	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
32	A prospective, randomized evaluation of the feasibility of exergaming on patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 584-590.	1.3	32
33	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 255-263.	1.3	14
34	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2207.	2.2	21
35	Treosulfan, Fludarabine and Cytarabine As Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 5702-5702.	0.6	1
36	Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients. <i>Blood</i> , 2018, 132, 4625-4625.	0.6	2

#	ARTICLE	IF	CITATIONS
37	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2018, 132, 3399-3399.	0.6	1
38	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 1016-1016.	0.6	0
39	Vaccination of allogeneic hematopoietic stem cell transplant recipients—what should be considered?. <i>Annals of Hematology</i> , 2017, 96, 701-702.	0.8	2
40	Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1613-1619.	1.2	20
41	Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e129-e131.	1.7	19
42	Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 337-345.	1.2	17
43	Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation. <i>International Journal of Cancer</i> , 2016, 138, 1792-1801.	2.3	42
44	Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2603-2610.	1.2	7
45	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3504-3504.	0.6	0
46	Successful stem cell transplantation in a patient with primary cutaneous aggressive cytotoxic epidermotropic CD8 ⁺ T-cell lymphoma. <i>British Journal of Dermatology</i> , 2015, 173, 869-871.	1.4	10
47	Psychosocial interventions for adolescents and young adult cancer patients: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 370-386.	2.0	106
48	Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects. <i>Radiotherapy and Oncology</i> , 2015, 116, 287-293.	0.3	6
49	Modulation of lymphocyte subpopulations by extracorporeal photopheresis in patients with acute graft-versus-host disease or graft rejection. <i>Leukemia and Lymphoma</i> , 2015, 56, 671-675.	0.6	19
50	Long-Term Follow-up After Allogeneic Stem Cell Transplantation. <i>Deutsches Arzteblatt International</i> , 2015, 112, 51-8.	0.6	39
51	Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma. <i>Molecular and Clinical Oncology</i> , 2014, 2, 773-782.	0.4	8
52	Validation of the grip test and human activity profile for evaluation of physical performance during the intermediate phase after allogeneic hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2013, 21, 1121-1129.	1.0	24
53	Personality influences quality-of-life assessments in adult patients after allogeneic hematopoietic SCT: results from a joint evaluation of the prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center. <i>Bone Marrow Transplantation</i> , 2013, 48, 129-134.	1.3	22
54	Treatment options for graft-versus-host disease. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 731-743.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 767-776.	2.0	49
56	Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XMO2 in healthy donors. <i>Bone Marrow Transplantation</i> , 2013, 48, 922-925.	1.3	24
57	Comorbidity Significantly Impairs Quality Of Life In Patients After Allogeneic Hematopoietic Stem Cell Transplantation – Results From The Prospective German Multicenter Validation Trial. <i>Blood</i> , 2013, 122, 2073-2073.	0.6	1
58	Immune Responses to RHAMM in Patients with Acute Myeloid Leukemia after Chemotherapy and Allogeneic Stem Cell Transplantation. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	28
59	Chronic Graft versus Host Disease but not the Intensity of Conditioning has Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Hematological Diseases. <i>Onkologie</i> , 2012, 35, 3-3.	1.1	3
60	Time-dependent post-imperative negative variation indicates adaptation and problem solving in migraine patients. <i>Journal of Neural Transmission</i> , 2012, 119, 1213-1221.	1.4	11
61	The lack of memory B cells including T cell independent IgM+ α IgD+ memory B cells in chronic graft-versus host disease is associated with susceptibility to infection. <i>Transplant International</i> , 2012, 25, 87-96.	0.8	22
62	Immunization in the adult immunocompromised host. <i>Autoimmunity Reviews</i> , 2012, 11, 212-218.	2.5	68
63	Vaccination of allogeneic haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD. <i>Vaccine</i> , 2011, 29, 2825-2833.	1.7	93
64	Cholera vaccines. <i>Autoimmunity Reviews</i> , 2011, 11, 158.	2.5	0
65	Bilateral Breast Enlargement and Reddish Skin Macules as First Signs of Acute Lymphoblastic T Cell Leukemia. <i>Onkologie</i> , 2011, 34, 384-387.	1.1	1
66	Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. <i>Bone Marrow Transplantation</i> , 2011, 46, 1274-1275.	1.3	12
67	Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2011, 46, 502-509.	1.3	13
68	Expression of RHAMM and WT1 As Well As T Cell Responses to These Antigens Before and After Allogeneic Stem Cell Transplantation in Patients with Leukemia. <i>Blood</i> , 2011, 118, 4315-4315.	0.6	1
69	Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 4106-4106.	0.6	0
70	Use of the G-CSF Biosimilar Ratiograstim [®] to Mobilize Peripheral Stem Cells in Healthy Donors for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1928-1928.	0.6	2
71	Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2010, 12, 251-257.	0.7	19
72	Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning. <i>Journal of Clinical Oncology</i> , 2010, 28, 3344-3351.	0.8	83

#	ARTICLE	IF	CITATIONS
73	Multimodal Therapy for Localized Spinal Epidural Follicular Lymphoma. <i>Onkologie</i> , 2010, 33, 4-4.	1.1	6
74	Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1707-1717.	2.0	57
75	Lymphocyte Subsets In Chronic Gvhd â€œ a Key Role for B Cells?. <i>Blood</i> , 2010, 116, 2311-2311.	0.6	0
76	Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. <i>Experimental Hematology</i> , 2009, 37, 143-150.	0.2	8
77	Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2009, 159, 87-92.	1.1	29
78	Visual deterioration after gram-negative sepsis in neutropenia. <i>Annals of Hematology</i> , 2008, 87, 155-157.	0.8	0
79	Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2008, 87, 1009-1012.	0.8	20
80	Autoantibody-mediated agranulocytosis in association with chronic GVHD. <i>Bone Marrow Transplantation</i> , 2008, 42, 359-360.	1.3	1
81	Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. <i>Bone Marrow Transplantation</i> , 2008, 42, 541-546.	1.3	17
82	The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. <i>International Journal of Immunogenetics</i> , 2008, 35, 381-384.	0.8	45
83	Sirolimus in Combination with Tacrolimus in Allogeneic Stem Cell Transplantationâ€”Timing and Conditioning Regimen May Be Crucial. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 942-943.	2.0	15
84	Perforation of the Superior Vena Cava – a Rare Complication of Central Venous Catheters. <i>Onkologie</i> , 2008, 31, 262-264.	1.1	15
85	Continuous Therapy with Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Onkologie</i> , 2008, 31, 6-6.	1.1	3
86	Toxic epidermal necrolysis after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 245-246.	1.3	11
87	Enhanced vigilin and anionic trypsinogen expression in experimental chronic pancreatitis. <i>Open Medicine (Poland)</i> , 2007, 2, 159-167.	0.6	0
88	Incidence and Outcome of Non-CMV Viral Infections in 202 Consecutive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients.. <i>Blood</i> , 2007, 110, 1965-1965.	0.6	0
89	Headache after hematopoietic stem cell transplantation: Being aware of chronic bilateral subdural hematoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2247-2249.	0.6	5
90	T-cell-depleted stem cell boost for the treatment of autoimmune haemolytic anaemia after T-cell-depleted allogeneic bone marrow transplantation complicated by adenovirus infection. <i>Bone Marrow Transplantation</i> , 2006, 37, 977-978.	1.3	1

#	ARTICLE	IF	CITATIONS
91	Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplantation, 2006, 38, 445-451.	1.3	49
92	Canine Haematopoietic Chimerism Analyses by Semiquantitative Fluorescence Detection of Variable Number of Tandem Repeat Polymorphism. Veterinary Research Communications, 2005, 29, 103-110.	0.6	26
93	Influence of Hematopoietic Cell Lysate Vaccinations and Dendritic Cell Enriched Marrow Grafts on Engraftment after Nonmyeloablative Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 5231-5231.	0.6	0
94	Allogeneic Blood Stem Cell Transplantation in Patients with Hematologic Diseases after Conditioning with Treosulfan and Fludarabine.. Blood, 2005, 106, 2744-2744.	0.6	1
95	Vigilin and enzyme expression in isolated pancreatic acini after mellitin and gamma-interferon treatment. Pancreatology, 2003, 3, 336-341.	0.5	3
96	Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochemical Pharmacology, 2003, 66, 633-641.	2.0	62
97	Protein synthesis of eucaryotic cells could be decreased by antisense-DNA of the multi KH domain protein vigilin. International Journal of Molecular Medicine, 2003, 12, 35.	1.8	0
98	Protein synthesis of eucaryotic cells could be decreased by antisense-DNA of the multi KH domain protein vigilin. International Journal of Molecular Medicine, 2003, 12, 35-43.	1.8	2
99	Estradiol Has a Direct Impact on the Exocrine Pancreas as Demonstrated by Enzyme and Vigilin Expression. Pancreatology, 2001, 1, 24-29.	0.5	12